IFO50479 NAGL-1
Cell information
Cell type:general cells (View Pricing Information)
JCRB No. | IFO50479 | Cell Name | NAGL-1 |
---|---|---|---|
Profile | The CDR III of this line has been sequenced. | Other Name | |
Animal | human | Strain | |
Genus | Homo | Species | sapiens |
Sex | F | Age | |
Identity | available | Tissue for Primary Cancer | hemo-lymphocytic |
Case history | leukemia | Metastasis | |
Tissue Metastasized | Genetics | ||
Life Span | infinite | Crisis PDL | |
Morphology | round | Character | leukemia, B cells |
Classify | tumor | Established by | Abe, A. and Emi, N. |
Registered by | Emi,N. | Regulation for Distribution | |
Comment | Year | 1998 | |
Medium | Iscove's modification of Dulbecco's medium with 20% heat-inactivated fetal bovine serum | Methods for Passages | dilution |
Cell Number on Passage | 1-2 x 10^6 cells/ml | Race | |
CO2 Conc. | 5 % | Tissue Sampling | B cells |
Tissue Type |
Detection of virus genome fragment by Real-time PCR | |||||||||
---|---|---|---|---|---|---|---|---|---|
Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
BKV | - | HIV-1 | - | ||||||
JCV | - | HIV-2 | - | ||||||
ADV | - | HPV18 | - | ||||||
Notes |
Reference | |
---|---|
Pubmed id:10071461 | Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1. Kasai M,Akatsuka Y,Emi N,Taji H,Kohno A,Abe A,Tanimoto M,Kodera Y,Saito H Int J Hematol. 1999 Feb;69(2):112-8 |
Images |
---|
LOT Information
Cell No. | IFO50479 | Cell Name | NAGL-1 |
---|---|---|---|
LOT No. | 1142 | Lot Specification | distribution |
Medium | Iscov's modification of D.MEM, 80% ; heat-inactivated FBS, 20% | Temperature | 37 C |
Cell Density at Seeding | 1.8 x 10^6 cells/ml | Methods for Passages | Dilution. Split ratio, 1/2 - 1/3. For collection of cells, centrifuge at 1,200 rpm for 5 min. |
Doubling Time | Cell Number in Vial (cells/1ml) | 7.2 x 10^6 | |
Viability at cell freezing (%) | 90 | Antibiotics Used | free |
Passage Number | Unknown (12 at IFO) | PDL | |
Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
Sterility: FUNGI | - | Isozyme Analysis | NP, G6PD (type B), MD, AST |
Chromosome Mode | Chromosome Information | ||
Surface Antigen | DNA Profile (STR) | ||
Adhesion | No | Exoteric Gene | |
Medium for Freezing | 10% DMSO, 20% serum (final conc.)-culture medium | CO2 Conc. | 5 % |
Viability immediately after thawing (%) | Additional information |
Cell No. | IFO50479 | Cell Name | NAGL-1 |
---|---|---|---|
LOT No. | 11292013 | Lot Specification | distribution |
Medium | Iscove's modification of Dulbecco's medium with 20% heat-inactivated fetal bovine serum (GIBCO Cat. # 10091). | Temperature | 37C |
Cell Density at Seeding | 1.0 - 1.6 x 10^6 cells/mL | Methods for Passages | dilution |
Doubling Time | Cell Number in Vial (cells/1ml) | 1.3 x 10^7 (cells/1 | |
Viability at cell freezing (%) | Antibiotics Used | free | |
Passage Number | Unknown (19 at bank) | PDL | |
Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
Sterility: FUNGI | - | Isozyme Analysis | G6PD(typeB),NP,LDH were examined. Human,not HeLa |
Chromosome Mode | Chromosome Information | ||
Surface Antigen | DNA Profile (STR) | ||
Adhesion | Exoteric Gene | ||
Medium for Freezing | CO2 Conc. | 5% | |
Viability immediately after thawing (%) | 90.7 | Additional information |